Complete metabolic response rates by Lugano 2014 criteria. Response rates to pembrolizumab monotherapy, after 2 cycles of AVD and at EOT are shown (n = 30). *In 2 patients with early unfavorable stage cHL who received 4 cycles of AVD chemotherapy, diagnostic CT-scans substituted for PET4, as permitted by protocol at EOT.